1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Acceleron Ends ACE-083 FSHD Testing After Phase II Failure

 
• By Sten Stovall

Acceleron ended testing of ACE-083 in facioscapulohumeral muscular dystrophy after the investigational drug missed Phase II endpoints.

Muscular_Dystrophy
Acceleron Has Discontinued ACE-083 in facioscapulohumeral muscular dystrophy • Source: Shutterstock

In its second clinical failure in under six months, Acceleron Pharma Inc. has ended development of its investigational agent ACE-083 in facioscapulohumeral muscular dystrophy (FSHD) after the locally acting Myostatin+ agent failed to meet secondary endpoints in a mid-stage study.

In April, the Boston-based group stopped development of ACE-2494, a systemic muscle agent that it had been studying in a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

J&J Secures Another Indication On Caplyta’s Path To $5bn In Sales

 
• By Mandy Jackson

The US FDA approved Caplyta (lumateperone) as an adjunctive treatment for major depressive disorder, the third indication for a drug J&J expects to deliver $5bn in peak sales.

Five Things To Know About AbbVie’s Q3 Sales And Earnings Report

 
• By Joseph Haas

AbbVie stressed its continued revenue growth driven by Skyrizi and Rinvoq, while trying to sound unconcerned about unsettled drug-pricing policies such as MFN negotiations.

Novartis Still Has Significant M&A Firepower After Avidity Acquisition

 
• By Kevin Grogan

The Basel-based company has faith in its existing rare disease commercial platform to successfully market the newly-acquired assets.

Alkermes To Buy Avadel, Jumpstarting A Move Into Commercial Sleep Market

 
• By Jessica Merrill

The company will gain Lumryz, an oxybate for narcolepsy, paving the commercial path ahead of the eventual launch of its own Phase III-ready asset alixorexton.

More from Therapy Areas

Lilly’s Eloralintide Success Sets Bar For Amylin Rivals

 
• By Andrew McConaghie

The US pharma giant may have a best-in-class amylin agonist to go with incretin blockbuster Zepbound, but challengers could still go one better on safety and tolerability.

Lilly, Novo Lower US Obesity Drug Prices To Secure Government Coverage

 
• By Jessica Merrill

Wegovy and Zepbound will cost around $250 per month under Medicare and Medicaid, and the drugs will cost around $350 per month through TrumpRx.

Lilly Plans Phase III Trials After Positive Results From Amylin Drug Eloralintide

 
• By Alaric DeArment

The drugmaker presented positive data from its Phase II study at ObesityWeek that help validate the amylin class overall, which includes more than a dozen entrants.